FDA Approves Enhertu for Two New Early HER2+ Breast Cancer Indications
AZN sits 42% above its 52-week low of $129.15.
Summary
AstraZeneca and Daiichi Sankyo's Enhertu has received US FDA approval for two new indications in HER2-positive early breast cancer, expanding its use into neoadjuvant and adjuvant settings.
Key Events · Product Development and Regulatory · AZN
-
FDA Approval for Early Breast Cancer
Enhertu (trastuzumab deruxtecan) has been approved by the US FDA for two new indications in HER2-positive early breast cancer: neoadjuvant (before surgery) and adjuvant (following surgery).
-
Strong Clinical Efficacy
In the neoadjuvant setting (DESTINY-Breast11), Enhertu showed an 11.2% improvement in pathologic complete response (pCR) rate. In the adjuvant setting (DESTINY-Breast05), it reduced the risk of invasive disease recurrence or death by 53%.
-
Expanded Market Opportunity
These approvals bring Enhertu into curative-intent settings, reinforcing its role across stages of HER2-positive breast cancer and expanding its market potential.
-
Milestone Payment to Daiichi Sankyo
AstraZeneca will pay Daiichi Sankyo $155 million in milestone payments for these two indications, as sales of Enhertu in the US are recognized by Daiichi Sankyo.
Analysis · AZN · Life Sciences
The US FDA approval of Enhertu for use before and after surgery in HER2-positive early breast cancer significantly expands the drug's market potential into curative-intent settings. This approval is based on strong Phase III data showing improved pathologic complete response rates and a substantial reduction in disease recurrence, reinforcing Enhertu's role as a foundational treatment and offering new hope for patients at risk of recurrence.
At the time of this filing, AZN was trading at $183.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $284.1B. The 52-week trading range was $129.15 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.